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Introduction
In the two decades since the amyloid hypothesis was ﬁ  rst 
proposed [1], a great deal of evidence has accrued in 
support of this mechanism in the pathogenesis of 
Alzheimer’s disease (AD), mostly from preclinical studies 
of transgenic mice, autosomal dominant presenilin cases, 
and  in vitro data supporting the neurotoxic eﬀ  ects of 
amyloid-beta (Aβ). Th   e theoretical promise of this model, 
however, has yet to be realized in the world of AD 
therapeutics. Robust treatments still seem elusive, even 
with an identiﬁ   ed therapeutic target. Others have 
addressed the question of why this may be the case [2,3], 
and this review builds on that literature.
Th  e process of drug development, from preclinical 
investigation through phase III study, is shown in 
Figure  1. Considering each phase separately helps to 
identify confounders that might be driving a type II error, 
if such an error exists in reference to new drug 
development for AD.
Zahs and Ashe [2] reviewed mouse models of AD and 
made several observations in regard to translational 
research. Th   ese authors identiﬁ  ed more than 300 reports 
of eﬀ   ective AD interventions based on these models. 
Th   ey noted, however, that none of the models is actually 
a complete replication of AD. In fact, what the models do 
simulate is a presymptomatic phase of AD, which might 
correspond to a time many years before a patient would 
present to a memory clinic or a subject would present to 
a clinical trial.
Becker and Greig [3] identiﬁ   ed approximately 100 
candidate drugs for AD with more than 40 diﬀ  erent 
mechanisms of action, and 20 of those 100 drugs showed 
early promise through phase II studies. Table 1 of the 
authors’ report shows a representative sample of 16 drugs 
trialed within the last decade, and most of them failed 
because of lack of eﬃ   cacy in phase III study. Trials of 
these drugs are reviewed in more detail below.
Immunotherapy: AN1792
Th  is was the ﬁ  rst trial in humans of an active immuno-
therapy approach, in which Aβ42 was introduced as an 
antigen to stimulate antibody production against the entire 
Aβ molecule, thus promoting clearance of amyloid. 
AN1792 is unique among the drugs discussed here because 
it ceased development because of safety concerns related to 
the occurrence of meningoencephalitis, a T cell-mediated 
inﬂ   ammatory process that occurred in 6% of treated 
patients [4]. Responders were noted to have functional 
beneﬁ   t after one to three doses, and antibodies were 
persistent for 5 years or more [5]. Overall, clinical beneﬁ  ts 
of the vaccine were modest, although survivor analysis 
favored treatment [5]. However, a post hoc study of subjects 
who were enrolled in the AN1792 study and who came to 
autopsy revealed that immunization with Aβ42 (AN1792) 
resulted in clearance of amyloid plaques in patients with 
AD but this clearance did not prevent progressive 
neurodegeneration [6]. Limited data from the trial 
suggested that immunotherapeutic interventions should be 
administered early in the course of the disease. Second-
generation immunotherapy trials are now in progress.
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Phenserine, a derivative of physostigmine, is a selective, 
noncompetitive acetylcholinesterase inhibitor that has 
additional eﬀ  ects on Aβ levels [7]. Phenserine interacts 
with the 5’- untranslated region of the APP (amyloid beta 
(A4) precursor protein) gene and reduces translation of 
APP mRNA into protein. Both the (−)- and the 
(+)-enantiomer of phenserine are equipotent in dose-
dependent and time-dependent negative regulation of 
APP mRNA translation, but (+)-phenserine (posiphen) is 
inactive as an acetylcholinesterase inhibitor and therefore 
may be administered at higher doses [8].
In a phase IIb study in 20 patients with mild AD, 
phenserine 30 mg/day reduced cerebrospinal ﬂ  uid (CSF) 
levels of Aβ as well as formation of amyloid plaques (as 
measured by retention of cortical Pittsburgh compound 
B-positron emission tomography, or PIB-PET) [9]. In a 
6-month phase III trial in 384 patients with mild to 
moderate AD (Mini-Mental State Examination (MMSE) 
score of at least 10 and not more than 26), participants 
were randomly assigned to receive phenserine 10 or 
15 mg twice daily or placebo. At the completion of the 
trial, no signiﬁ  cant diﬀ  erences were found between the 
phenserine and placebo groups on the Alzheimer’s 
Disease Assessment Scale-cognitive subscale (ADAS-cog) 
or the Clinician’s Interview-Based Impression of Change 
(CIBIC), the primary outcome measures. Two concurrent 
clinical trials were halted, and the data from these were 
merged for analysis, which also failed to demonstrate 
beneﬁ  t of phenserine compared with placebo [10].
AZD3480 is an α4β2-selective nicotinic acetylcholine 
receptor (nAChR) agonist [11]. nAChRs in the central 
nervous system (CNS) are believed to be the primary 
cholinergic receptors lost in AD, and agonists at these 
receptors were hypothesized to be viable symptomatic 
treatments. In the Sirocco Trial, subjects with mild to 
moderate AD (n = 659) were randomly assigned to 
receive one of three doses of AZD3480, a ﬁ  xed dose of 
donepezil, or placebo for 12 weeks [12]. Although 
AZD3480 was comparable to placebo in terms of its 
overall safety and tolerability proﬁ  le and was associated 
with fewer gastrointestinal-related adverse eﬀ  ects than 
donepezil, neither AZD3480 nor donepezil was 
signiﬁ  cantly positive on the primary outcome measure 
Figure 1. The process of drug development from preclinical investigation through phase III study, with potential confounders. MMSE, 
Mini-Mental State Examination.
Pre-clinical studies x  Poor correspondence of animal models
to human disease.
Phase I studies x  Focus on safety; efficacy signal is
relatively unattended.
x  Wrong dose or route of drug.
x  Wrong stage of disease targeted.
Phase II studies
Phase III studies x  Increased heterogeneity of sample
compared to Phase II.
x  More raters with less experience.
x  MMSE used for inclusion/exclusion.
x Flawed  outcome  measures.
x Short  study  durations.
x  High placebo response rates.
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improvement in the placebo group over time aﬀ  ected 
outcome. In addition, there was some concern that the 
study was too brief to detect a positive outcome, even for 
a symptomatic treatment. Th  e minimum duration of a 
treatment trial is usually on the order of 24 weeks.
Neuroprotection: Ginkgo biloba
G. biloba is an herbal supplement that is widely believed 
to have eﬃ   cacy in the prevention and treatment of aging-
associated cognitive decline, including AD. Evidence 
suggests that this drug facilitates the clearance of Aβ 
through regulation of the receptor for advanced glycation 
end-products and LRP-1 (low density lipoprotein receptor-
related protein 1) during brain ischemia [13]. Studies of 
the eﬃ     cacy of this drug have had mixed results. An 
important and inﬂ  uential study was the National Insti-
tutes of Health-sponsored clinical trial at ﬁ  ve academic 
medical centers between 2000 and 2008; in that study, an 
extract of G. biloba 120 mg twice daily or placebo was 
administered to 3,069 elderly community-dwelling volun-
teers (2,587 with normal cognition and 482 with amnestic 
mild cognitive impairment, or MCI) [14]. Participants 
were evaluated every 6 months for the primary outcome 
measures of incident dementia and AD (determined by 
expert panel consensus). Th   e results indi  cated no signiﬁ  -
cant eﬀ  ect of G. biloba on the progression to AD (hazard 
ratio (HR) = 1.16, 95% conﬁ  dence interval (CI) 0.97 to 
1.39) or all-cause dementia (HR = 1.12, 95% CI 0.94 to 
1.33). A subset analysis in participants with amnestic 
MCI at baseline had similar results (HR = 1.13, 95% CI 
0.85 to 1.50). Overall, a greater number of subjects 
treated with G. biloba developed dementia (n = 277; 3.3 
per 100 person-years) in comparison with placebo (n = 
246; 2.9 per 100 person-years), but the diﬀ  erence was not 
statistically signiﬁ  cant.  Th  e  ﬁ   ndings of this study 
suggested no role for G. biloba in the preven  tion of AD or 
incident cognitive decline [14,15]. Meta-analyses of the 
studies of G. biloba in the treatment and prevention of 
dementia and cognitive decline show variable eﬀ  ects with 
an inconsistent signal [16,17]. Th   e data in aggregate are 
contrary to the widely held view that Ginkgo prevents 
memory decline and, in fact, are contrary to earlier 
ﬁ  ndings. In the larger community of outpatients, it is 
possible that Ginkgo self-administration is actually a 
marker for a healthy lifestyle, with high compliance by 
virtue of voluntary administration.
Glutamatergic drugs: neramexane and SGS742
Neramexane is an N-methyl D-aspartate (NMDA) recep-
tor antagonist similar to memantine. Th  ese drugs are 
thought to reduce excitoxicity associated with excessive 
glutamatergic stimulation. In phase II trials, neramexane 
demonstrated reasonable safety and tolerability [18]. 
Presumably because of poor eﬃ   cacy, the drug was not 
entered into phase III trials for AD; instead, the drug is 
under investigation for the treatment of tinnitus and 
pain. Given the mechanism of the drug, it would not be 
expected to inﬂ  uence disease progression in AD.
SGS742 is an orally active phosphoamino acid deriva-
tive that acts as a selective gamma-aminobutyric acid 
type B (GABAB)-receptor antagonist [19]. Th   is drug was 
considered as a potential treatment for AD because 
activation of GABAB receptors had been found to inhibit 
memory/learning in animal models [19]. It was hypo  the-
sized that GABAB antagonists might reverse this eﬀ  ect by 
reducing glutamatergic excitotoxicity via in  direct eﬀ  ects 
on NMDA receptors. Preclinical studies in rats, mice, 
and rhesus monkeys were positive. In the ﬁ  rst phase II 
trial (n = 110) in MCI, SGS742 was well tolerated at a 
dose of 600 mg three times daily for 8 weeks [19]. Positive 
eﬀ  ects on attention, visual information processing, and 
working memory were demonstrated. In a phase IIb 
monotherapy trial (n = 280) in mild to moderate AD, 
SGS742 failed to meet the eﬃ   cacy endpoints.
Hormonal therapies: estrogen and leuprolide
Hormone replacement therapy (HRT) has been proposed 
as a target for treatment and prevention in AD because of 
dampening eﬀ   ects on Aβ demonstrated in preclinical 
studies [20,21]. A meta-analysis of 10 studies linked 
estrogen with a higher risk of dementia, a lower risk of 
dementia, and no association with dementia or AD [22]. 
A second meta-analysis noted a slight but inconsistently 
positive eﬀ  ect of estrogen on cognitive health [23]. A 
third meta-analysis concluded that, given the problems 
with study conduct and methodology plaguing studies of 
estrogen and cognition, the association between HRT 
and dementia risk was still unknown [24].
Results of the Women’s Health Initiative Memory 
Study (WHIMS) indicate that HRT was not associated 
with a lower risk of dementia and in fact may be 
associated with an increased risk of dementia [25]. 
Subjects administered the combined HRT regimen of 
estrogen and progestin were twice as likely to develop 
dementia in comparison with those not treated with 
HRT. In a later WHIMS study, which looked at the use of 
estrogen monotherapy for women who previously had a 
hysterectomy, subjects on HRT had a 49% higher 
incidence of probable dementia during follow-up [26]. 
Both estrogen trials were terminated − estrogen and 
progestin in July 2002 and estrogen alone in February 
2004 − because of adverse cardiovascular and stroke 
events and concern over increased breast cancer risk.
Trials of HRT in subjects with established AD have also 
been mostly negative. If HRT is to be pursued as prophy-
laxis or treatment of AD, the investigation will likely 
focus on several unresolved issues, including the timing 
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ences with the use of bioidentical or synthetic hormones.
As age is the leading risk factor for AD, the question of 
whether the cause of AD is also age-related naturally 
arises. It is well established that estrogen and testosterone 
levels decline with age and that levels of follicle-
stimulating hormone (FSH) and luteinizing hormone 
(LH) rise because of reduced negative feedback to the 
HPA axis [27]. Th  ese gonadotropins stimulate not only 
gonadal steroid synthesis but also cell proliferation in the 
gonads, where AβPP and presenillins are highly 
expressed. LH receptors are present on neurons and are 
particularly abundant in the hippocampus. A preclinical 
study suggested that lowering LH levels might be 
beneﬁ   cial in AD [28]. Increased LH levels have been 
found in brain in patients with AD [29,30]. Treatment of 
C57/Bl6 wild-type mice with leuprolide decreases Aβ 
levels. Leuprolide is known to lower LH levels in humans 
and is marketed for the treatment of prostate cancer. In 
phase III trials, however, leuprolide failed because of lack 
of eﬃ   cacy.
Serotonin 5HT1A receptor antagonists: xaliproden
Xaliproden was considered for the treatment of AD 
because of its nerve growth factor-like eﬀ  ects and its 
antagonism of the serotonin 1A (5-HT1A) receptor [31]. 
Consideration of 5-HT1A antagonists for AD was based 
on preclinical data indicating that they facilitated 
glutamatergic and cholinergic neurotrans  mission [31] 
and that inhibition of the 5-HT1A receptor resulted in the 
enhancement of cognitive abilities [31]. Two large phase 
III, 18-month clinical trials of xaliproden monotherapy 
(n = 1,306) and adjunctive therapy (n = 1,455) in patients 
with mild to moderate AD (MMSE score of 16 to 26) 
were completed in 2007 [32]. Lack of eﬃ   cacy in both 
trials resulted in the cancellation of the xaliproden 
development program for AD in September 2007.
Gamma secretase modulator: tarenfl  urbil
Tarenﬂ  urbil, the r-enantiomer of the nonsteroidal anti-
inﬂ   ammatory drug ﬂ   urbiprofen, was the ﬁ  rst  gamma-
secretase modulator to reach the ﬁ  nal stage of clinical 
development. Results of a phase II trial in 210 patients 
studied for 18 months did not meet the primary end-
point, but a post hoc analysis of subjects with mild AD 
(MMSE score of 20 to 26) found beneﬁ  cial  eﬀ  ects  of 
tarenﬂ  urbil at a dose of 800 mg twice daily in terms of 
measures of daily activities and global function [33].
Th   e 18-month phase III trial (n = 1,600), conducted at 
133 sites in the US, examined the eﬀ  ect of tarenﬂ  urbil 
800 mg twice daily in patients with mild AD (mean 
MMSE score of 23, range of 20 to 26), 81% of whom were 
receiving a stable dose of an acetylcholinesterase inhibi-
tor, memantine, or a combination of these drugs [34]. Th  e 
primary outcome measures were the ADAS-cog and 
ADAS activities of daily living (ADAS-ADL) scale, 
assessed every 3 months. Th   ere was no signiﬁ  cant diﬀ  er-
ence between the tarenﬂ  urbil and placebo groups; at the 
end of the study, both groups had declined by mean 
values of 7 points on the ADAS-cog and 10 points on the 
ADAS-ADL. With this magnitude of decline over 
18  months, an eﬃ   cacy signal should have been detec-
table. It is possible, as some have speculated, that 
tarenﬂ  urbil given orally did not adequately penetrate the 
CNS. It is also possible that gamma secretase modulation 
is best initiated before any plaque deposition has 
occurred (for example, in patients at risk of AD) and 
therefore would exert minimal eﬀ   ects with signiﬁ  cant 
amyloid burden as is common in symptomatic AD.
Statin drugs
Elevated midlife cholesterol levels are associated with an 
increased risk of AD [35], and chronic use of hydroxy-
methylglutaryl coenzyme A-reductase inhibitors (statins) 
has been reported to reduce the risk of developing AD by 
up to 75% [36]. In addition, robust scientiﬁ  c data indicate 
that hypercholesterolemia promotes Aβ production and 
deposition in a variety of animal models of AD and that 
cholesterol reduction strategies reduce Aβ deposition 
[37]. Another study indicates that statins inhibit Aβ 
formation in vitro [38].
Although a phase II study of atorvastatin 80 mg/day 
monotherapy in 63 patients with mild to moderate AD 
found that the treated group had no deterioration in 
scores on cognitive or functional assessment scales after 
12 months of treatment [35], a larger phase III study 
(n  =  600) in patients also receiving donepezil was 
completed in 2007 and found no beneﬁ  t to adjunctive use 
of atorvastatin [39]. A phase III trial (n = 400) of simva-
statin monotherapy was also completed in 2007, and the 
results were reported to be negative as well.
Despite these negative ﬁ  ndings, the epidemiologic data 
suggesting a protective eﬀ  ect (as opposed to a treatment 
eﬀ  ect) of statins in AD [40] are suﬃ   ciently encouraging 
that simvastatin 80 mg/day is now in a phase II trial 
prevention study. Th   is study plans to enroll 100 adults (35 
to 69 years old) who have a parent with AD but who do 
not themselves exhibit any cognitive deﬁ  cits. Th  e  primary 
outcome measures are CSF Aβ, inﬂ  ammatory markers, 
and cholesterol as well as cognitive performance over 
time (Evaluating Simvastatin’s Potential Role In Th  erapy 
(ESPRIT) [32].
Insulin sensitizer: rosiglitazone
Insulin signaling is known to have a role in memory 
function and may also inﬂ  uence the regulation of APP 
and Aβ [41]. In addition, insulin-degrading enzyme is 
one of the enzymes active in clearance of Aβ [42]. For 
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causes of or contributors to cognitive impairment, and 
insulin resistance has been proposed as a potential target 
for AD prevention. Rosiglitazone acts as an insulin 
sensitizer, binding to receptors in fat cells that render the 
cells more responsive to insulin [43]. In the phase II trial 
(n = 511), no diﬀ  erence between the rosiglitazone and 
placebo groups was found in the population as a whole, 
but an interaction between ApoE  ε4  genotype and 
outcome was identiﬁ  ed in those on the highest dose of 
drug [44]. Speciﬁ  cally,  non-ε4  carriers were found to 
improve on rosiglitazone 8  mg. No serious safety 
concerns were noted. In the phase III trials, patients were 
stratiﬁ  ed  by  ApoE  ε4 status. Regardless of whether 
rosiglitazone was used as monotherapy or adjunctive 
therapy, eﬃ     cacy for mild to moderate AD was not 
demonstrated by either the ADAS-Cog or the CIBIC-
plus. In meta-analyses unrelated to AD trials, cardio-
vascular morbidity with rosiglitazone was identiﬁ  ed [45]. 
Th   is safety concern will likely limit the scope of 
investigation for rosiglitazone for AD.
Glycosaminoglycan mimetic: tramiprosate
Structurally, tramiprosate is a glycosaminoglycan (GAG) 
mimetic designed to interfere with the actions of Aβ early 
in the cascade of amyloidogenesis [46]. Tramiprosate is a 
modiﬁ  cation of the amino acid taurine. It binds prefer  en-
tially to soluble Aβ peptide and maintains Aβ in a 
nonﬁ  brillar form, thereby inhibiting amyloid formation 
and deposition. Tramiprosate also interferes with β-sheet 
formation of amyloid.
In the phase II clinical trial, subjects randomly assigned 
to tramiprosate demonstrated sustained safety and 
tolerability as well as a reduction in CSF Aβ42 levels [47]. 
Additionally, the treated subjects remained near baseline 
as measured by ADAS-Cog after 20 months of treatment.
Th   e phase III trial, which was conducted in 67 centers 
throughout North America, randomly assigned 1,052 
patients with mild to moderate AD to tramiprosate 100 
and 150 mg twice daily or placebo [48]. Continued use of 
approved AD medications was allowed. Th  e primary 
endpoints were the ADAS-Cog score, the Clinical 
Dementia Rating Scale-Sum of Boxes score, and change 
in hippocampal volume on magnetic resonance imaging. 
Tramiprosate was not signiﬁ  cantly more eﬀ  ective than 
placebo on any of these outcome measures. In November 
2007, the sponsor announced its intention to discontinue 
development of tramiprosate as a pharmaceutical and 
halted the European phase III trial. Again, a confounder 
of the phase III trial was an unusually strong placebo 
response [48]. In addition, there is some evidence that 
tramiprosate acts to promote the aggregation of tau 
protein [46]. Since 2008, tramiprosate has been marketed 
as the over-the-counter nutraceutical Vivimind.
Chelating agents: clioquinol (PBT1)
Proponents of chelation therapy have focused on 
identifying and extracting metallic ions co-localized to 
plaques. Clioquinol, an anti-malarial drug no longer used 
(because of toxicity to peripheral and optic nerves), has 
been shown to inhibit zinc and copper ions from binding 
to Aβ, thus promoting the solubilization and clearance of 
Aβ. A pilot phase II clinical trial was conducted in 36 
subjects with moderate AD. Th  e  eﬀ  ect of treatment was 
signiﬁ  cant in the more severely aﬀ  ected group (baseline 
ADAS-Cog score of at least 25) but the eﬀ  ect  was 
attributed to substantial worsening of scores in those 
taking placebo in comparison with minimal deterioration 
for the clioquinol group. Plasma Aβ42 levels declined in 
the clioquinol group and increased in the placebo group. 
Plasma zinc levels rose in the clioquinol-treated group. 
Th  e drug was well tolerated. Th  ese data suggest that 
clioquinol improved cognition and lowered plasma levels 
of Aβ42 in some patients. However, a phase III study was 
never undertaken and clioquinol is no longer in develop-
ment for the treatment of AD [49].
Conclusions
In general, review of failed drug trials in AD can be 
productive if pitfalls that can be avoided in future trials 
are identiﬁ  ed. Several general ﬁ  ndings are worth noting. 
Except for the early vaccine trials and rosiglitazone, the 
major obstacle facing drug development over the last 
decade appears to be lack of demonstrated eﬃ   cacy rather 
than safety. Th   e logical possibilities to explain ineﬃ   cacy 
are that the drugs developed thus far are simply 
ineﬀ  ective in humans, that the amyloid hypothesis is not 
the right model, that the drugs are administered incor-
rectly (wrong dose, route, or disease stage), or that the 
drugs are working but the clinical trial complex is unable 
to detect the signal.
The drugs are not eff  ective in humans
Th   e possibility does exist that, at least for some of the 
drugs trialed, preclinical data are misleading. In vitro 
models may be too simplistic, lacking the complex 
interactions of pharmacokinetics and pharmaco  dy-
namics with physiology. Transgenic mouse models do 
not provide a true representation of AD, as noted 
earlier. Many of the models lack pathological charac-
teristics such as tangles, or plaque morphology and 
dissolution characteristics are diﬀ  erent from those of 
human AD plaque. Th   us, some drugs shown to work in 
vitro and in vivo may never be eﬃ   cacious in humans. 
Alternatively, since animal studies are not a true reﬂ  ec-
tion of the disease process in AD in humans, the disease 
in humans may be too advanced or too widespread at 
the sympto  matic phase to be amenable to meaningful 
clinical eﬀ  ect.
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It would be diﬃ   cult at this point to argue that the amyloid 
hypothesis does not describe at least some component of 
the pathogenetic pathway of AD. Amyloid immuno-
therapies have become a common approach to targeting 
the disease, but the results to date have not been 
consistently positive nor does targeting amyloid patho-
logy change the outcome [6]. Th   is does not rule out the 
possibility, however, that tau or other pathologies (or 
both) should also be targeted.
The drugs are administered incorrectly
Clinical trialists working in phase II and III studies have 
to trust that adequate time and attention have been paid 
in earlier phases of drug development to the identiﬁ  cation 
of the appropriate drug dose. For the most part, this has 
not proven problematic. More important to drug success 
is the observation, already stated, that the AD mouse 
model more closely parallels preclinical AD, so for drugs 
developed along this pathway, the focus of investigation 
should be on asymptomatic at-risk individuals or those 
with very early MCI. For the latter group, it would be 
important to avoid using the MMSE as a screening tool 
for subject inclusion/exclusion. In part because of ceiling 
eﬀ  ects and in part because of practice eﬀ  ects with the 
MMSE, potential subjects are often excluded by this 
measure even though it is clear that they are impaired 
from baseline. A more sensitive screening instrument 
such as the Montreal Cognitive Assessment could be 
used in place of the MMSE [50].
The drugs work but clinical trials are not detecting effi   cacy
Of the available explanations for failed trials, this appears 
to be the most likely candidate. Even a cursory look at 
clinical trial conduct reveals a number of potential 
problems, many of which are amenable to correction. 
One of the most signiﬁ  cant problems from the standpoint 
of the clinical trialist is the heavy reliance on rating scales 
as outcome measures [3]. Regardless of the quality of 
rater training, any degree of subjectivity in assessment 
will introduce variance across sites and over time. Even 
for ostensibly ‘objective’ instruments such as the ADAS-
Cog, which is the most widely used measure of cognitive 
change in AD trials, variations in forms, administration 
procedures, and scoring rules exist [51]. More widespread 
use of human amyloid imaging is a critical next step in 
the improvement of outcome measures for AD trials.
Th  e fact that so many of the AD drug trials failed in 
moving from phase II to phase III provides a clue as to 
other problems plaguing drugs under investigation. One 
factor that changes between these two phases is that the 
study population becomes more heterogeneous, and with 
this change comes the possibility that as-yet-unidentiﬁ  ed 
confounding medical problems and medications will be 
introduced. As trials get larger, are ‘less eligible’ subjects 
enrolled? In addition, the group of trialists and research 
centers expands in moving to phase III, reaching out 
beyond the inner circle of investigators and coordinators. 
At least in some trials, the added personnel are relatively 
lacking in experience with the drug, not having been 
involved in phase I or II activities.
Another issue relates to the short duration of many 
clinical trials. Long trials are very diﬃ   cult to conduct in 
elderly patients with a progressive disease like AD, 
particularly since it also so profoundly aﬀ  ects caregivers, 
who usually serve as study partners. In addition, new 
drug development is big business, and the push to obtain 
data in support of a new drug application is a fact of life 
for the pharmaceutical industry. Th  ose who conduct 
clinical trials are sometimes left to wonder whether an 
extension might turn a negative trial into a positive one.
Unexpected and large improvements in placebo 
populations have plagued several of the trials for AD. 
Th  is improvement is actually understandable from the 
point of view of the clinical trialist. Individuals enrolled 
in AD trials are seen on a regular basis by caring 
individuals who have a good understanding of how to 
talk to patients with dementia and how to deal with 
problematic behaviors. Whether speciﬁ  c  non-trial-
related interventions are undertaken or not, positive 
interactions at these visits are bound to have beneﬁ  cial 
eﬀ  ects. Th   is is a diﬃ   cult area to remedy without oﬀ  ense, 
but some thought should be given to ways in which the 
patient contacts could be ‘sterilized’ to help neutralize 
this eﬀ  ect. In addition, it could be expected that, given 
enough time, the placebo group would naturally decline. 
Perhaps a rule of thumb could be stated as follows: if your 
placebo group does not decline, your trial is too short.
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